How should memantine be initiated in an older patient with moderate-to-severe Alzheimer disease, including dosing schedule and renal function adjustments?

How to Initiate Memantine

Start memantine at 5 mg once daily and titrate up by 5 mg increments weekly to a target dose of 20 mg/day (10 mg twice daily), with dose reductions required only in severe renal impairment (creatinine clearance 5-29 mL/min, target 5 mg twice daily). 1

Standard Titration Schedule

The FDA-approved dosing regimen follows a structured 4-week titration:

• Week 1: 5 mg once daily
• Week 2: 10 mg/day (5 mg twice daily)
• Week 3: 15 mg/day (5 mg and 10 mg as separate doses)
• Week 4 and beyond: 20 mg/day (10 mg twice daily) - this is the therapeutic target dose 1

The minimum interval between dose increases is one week. 1 This gradual titration minimizes adverse effects while achieving therapeutic levels. The 20 mg/day dose has been shown to be effective in controlled clinical trials for moderate to severe Alzheimer's disease. 1, 2

Renal Function Adjustments

Severe renal impairment is the only indication for dose modification:

• Normal renal function (CrCl >80 mL/min): Standard 20 mg/day (10 mg twice daily) 3
• Mild renal impairment (CrCl 50-80 mL/min): Standard 20 mg/day (10 mg twice daily) - no adjustment needed 3
• Moderate renal impairment (CrCl 30-49 mL/min): Standard 20 mg/day (10 mg twice daily) - no adjustment needed 3
• Severe renal impairment (CrCl 5-29 mL/min): Target dose 5 mg twice daily (10 mg/day total) 1, 3

Pharmacokinetic studies demonstrate that area under the curve increases by 60% in moderate renal impairment and 115% in severe renal impairment, but steady-state concentrations remain within acceptable ranges at standard dosing for mild and moderate impairment. 3 Only severe renal impairment requires the reduced target dose of 5 mg twice daily to maintain therapeutic plasma levels without excessive accumulation. 3

Hepatic Impairment Considerations

Memantine should be administered with caution in patients with severe hepatic impairment, though no specific dose adjustment is mandated by the FDA label. 1 The evidence does not provide clear dosing modifications for hepatic dysfunction, so clinical judgment and closer monitoring are warranted in this population.

Administration Details

• Timing: Can be taken with or without food 1
• Formulation: Available as tablets or oral solution (2 mg/mL) 1
• Missed doses: If a single dose is missed, do not double the next dose; resume the regular schedule 1
• Extended interruption: If memantine is stopped for several days, dosing may need to be resumed at lower doses and retitrated using the standard schedule 1

Clinical Context and Evidence

Memantine is FDA-approved specifically for moderate to severe Alzheimer's disease. 1 The evidence base demonstrates statistically significant but not clinically dramatic improvements in cognition (measured by ADAS-cog and SIB scales), global function (CIBIC-plus), and quality of life measures. 4

Key efficacy findings from pivotal trials:

• In moderate to severe AD, memantine showed a 5.7-unit advantage over placebo on the Severe Impairment Battery (SIB) at 28 weeks 2
• Activities of daily living improved by 3.4 units on the ADCS-ADL scale compared to placebo 2
• When added to donepezil in patients already on stable cholinesterase inhibitor therapy, memantine provided additional benefits in cognition, function, and behavior 5

The Canadian Consensus Conference (2020) supports memantine use for moderate to severe AD, as well as for Parkinson's disease dementia, dementia with Lewy bodies, and vascular dementia. 6

Safety Profile

Withdrawal rates due to adverse events are low (9-12% with memantine vs 7-13% with placebo). 4 Common adverse effects include:

• Dizziness
• Confusion
• Dizziness
• Diarrhea
• Agitation 4

These effects are generally mild to moderate and do not differ substantially from placebo rates. 2, 7

Important Contraindications and Precautions

Absolute contraindication: Known hypersensitivity to memantine or any excipients 1

Genitourinary conditions: Conditions that raise urine pH (such as renal tubular acidosis or severe urinary tract infections) may decrease urinary elimination of memantine, resulting in increased plasma levels. 1 Monitor for increased adverse effects in these situations.

Other contraindications include:

• Uncontrolled asthma
• Angle-closure glaucoma
• Sick sinus syndrome
• Left bundle-branch block 4

Combination Therapy

Memantine can be safely combined with cholinesterase inhibitors (donepezil, rivastigmine, galantamine). 5 In fact, combination therapy with donepezil in moderate to severe AD showed superior outcomes compared to donepezil monotherapy across multiple domains including cognition, activities of daily living, global assessment, and behavior. 5

Monitoring for Response

A beneficial effect, if present, should generally be observed within 3 months based on trial durations. 4 This effect may manifest as improvement or stabilization of symptoms. 4 The 2020 Canadian guidelines recommend considering discontinuation if no clinically meaningful benefit is observed at any time during treatment or if there is clinically meaningful worsening over 6 months. 6